Press

Lobe Sciences Files Patent Application Covering the Preparation of Stable Psilocin Prodrugs and Analogues and their Uses Further Strengthening its Intellectual Property Portfolio

Jul 22 • 2 min read

Lobe Sciences Ltd. (CSE: LOBE | OTCQB: LOBEF), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has filed a provisional patent for the preparation and use of its proprietary and stable psilocin related compounds. “Our patent portfolio now consists of multiple patent filings…

Relmada Therapeutics Appoints Biopharmaceutical Marketing and Commercial Planning Veteran John Hixon as Head of Commercial

Jul 21 • 4 min read

Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the appointment of to a newly created position as Head of Commercial. Mr. Hixon has over 36 years of commercial planning and marketing experience within the biopharmaceutical industry. “My due diligence performed before joining Relmada, strongly…

Delic 2021 Revenue Shows Strong Growth as Nation’s Largest Ketamine Clinic Chain, Continues Expansion of Mental Health Wellness Services

Jul 21 • 4 min read

Delic Holdings Corp (CSE: DELC | OTCQB: DELCF | FRA: 6X0), a leader in new medicines and treatments for a modern world, is pleased to share the following corporate update: Delic Corp released its first annual end-of-year earnings report in May. In 2021 the Company generated more than USD$1.5MM in revenue and increased net assets…

Mydecine Files Full Patent Application Covering MYCO-006 Family of Novel Short-Acting MDMA Analogs

Jul 21 • 4 min read

Mydecine Innovations Group Inc. (NEO: MYCO | OTC: MYCOF | FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, announced it has successfully synthesized multiple short-acting MDMA analogs. This family of analogs have been specifically designed by experts at Mydecine to have a shorter half life than traditional…

Delic Labs President and CSO Dr. Markus Roggen Named to Cannabis Scientist Power List for Third Consecutive Year

Jul 20 • 3 min read

Delic Holdings Corp (CSE: DELC | OTCQB: DELCF | FRA: 6X0), a leader in new medicines and treatments for a modern world, today celebrated Dr. Markus Roggen, President and Chief Science Officer for Delic Labs, being named to the Cannabis Scientist Power List for the third consecutive year. Dr. Markus Roggen is consistently recognized as one of the most influential…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435